Somatostatin analogue inhibits intestinal regeneration
J. S. Thompson, B. L. Nguyen and R. F. Harty
Surgical Service, Veterans Affairs Medical Center, Omaha, NE.
Somatostatin analogue octreotide inhibits intestinal absorption and
motility but its effect on epithelial cell migration and proliferation
remains unclear. Our aim was to determine the effect of octreotide on
parameters of intestinal regeneration, including epidermal growth factor
(EGF)-induced changes. Thirty rabbits had full-thickness ileal defects
patched with cecal serosa surface. Group 1 were controls. Groups 2 and 3
received 100 micrograms and 1000 micrograms, respectively, of subcutaneous
octreotide daily. Group 4 received EGF at 1.5 micrograms/kg per hour via
subcutaneous miniosmotic pump, and group 5 received both octreotide (1000
micrograms/d) and EGF (1.5 micrograms/kg per hour). Octreotide at 100
micrograms/d did not inhibit epithelial cell migration or proliferation at
7 days. Octreotide at 1000 micrograms/d inhibited normal but not
EGF-stimulated cell migration. Octreotide decreased EGF-stimulated but not
normal proliferation. Octreotide impairs epithelial cell migration in a
dose-dependent manner. Octreotide inhibits EGF-stimulated proliferative
activity but not EGF-stimulated migration. Prolonged administration of
octreotide may adversely affect normal and adaptive intestinal regeneration
by both direct and indirect effects.
